PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsErythromycin
Erythromycin
Benzamycin, E.e.s, Ery-tab, Eryc, Erygel, Eryped, Erythrerm, Erythrocin, Erythromycin, Eryzole, Ilosone, Ilotycin, Pediazole (erythromycin) is a small molecule pharmaceutical. Erythromycin was first approved as Ilotycin on 1982-01-01. It is used to treat acne vulgaris, bacterial eye infections, bacterial infections, campylobacter infections, and chancroid amongst others in the USA. It is known to target motilin receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
respiratory tract diseasesD012140
eye diseasesD005128
urogenital diseasesD000091642
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Ery-tab, Eryc, Erygel, Erythrerm, Erythromycin (discontinued: A/t/s, Akne-mycin, C-solve, E-base, E-glades, E-mycin, Emgel, Eryc, Eryc sprinkles, Erycette, Eryderm, Erymax, Erythro-statin, Erythromycin, Ilotycin, Pce, R-p mycin, Robimycin, Sansac, Staticin, T-stat)
Combinations
Benzamycin, Erythromycin benzoyl peroxide (discontinued: Aktipak, Erythromycin benzoyl peroxide)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Erythromycin
Tradename
Company
Number
Date
Products
ERYCDr Reddys LaboratoriesN-050536 RX1982-01-01
1 products, RLD, RS
ERYGELMylanN-050617 RX1987-10-21
1 products, RLD, RS
Show 8 discontinued
Benzoyl peroxide
+
Erythromycin
Tradename
Company
Number
Date
Products
BENZAMYCINBausch Health CompaniesN-050557 RX1984-10-26
1 products, RLD, RS
Show 1 discontinued
Erythromycin gluceptate
Tradename
Company
Number
Date
Products
ILOTYCIN GLUCEPTATEDista ProductsN-050370 DISCN1982-01-01
3 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
benzamycinNew Drug Application2020-11-30
e.e.sNew Drug Application2011-04-18
e.e.s e.e.sANDA, New Drug Application2025-02-21
eryANDA2024-12-24
ery-pedNew Drug Application2024-12-24
ery-tabANDA2024-10-11
erygelNew Drug Application2018-06-21
erythrocin lactobionateANDA2024-02-22
erythrocin stearateANDA2015-07-31
erythromycinANDA2025-01-28
Show 9 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
acne vulgarisEFO_0003894D000152L70
bacterial infections—D001424A49
gonorrheaDOID_7551D006069A54
campylobacter infectionsEFO_0007190D002169—
whooping coughEFO_0000650D014917A37
chlamydia infectionsEFO_0007205D002690A74.9
streptococcal infectionsEFO_1001476D013290—
legionnaires' diseaseEFO_0007343D007877A48.1
urethritisEFO_0003878D014526N34
bacterial eye infections—D015818—
Show 8 more
Agency Specific
FDA
EMA
Expiration
Code
ERYTHROMYCIN, ERYTHROMYCIN, TORRENT
2022-04-02CGT
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D10: Anti-acne preparations
— D10A: Anti-acne preparations for topical use
— D10AF: Antiinfectives for treatment of acne
— D10AF02: Erythromycin
— D10AF52: Erythromycin, combinations
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01F: Macrolides, lincosamides and streptogramins
— J01FA: Macrolides
— J01FA01: Erythromycin
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AA: Antibiotics, ophthalmologic
— S01AA17: Erythromycin
HCPCS
Code
Description
J1364
Injection, erythromycin lactobionate, per 500 mg
Clinical
Clinical Trials
2356 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
RecurrenceD012008—————1—1
Acne vulgarisD000152EFO_0003894L70———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PneumoniaD011014EFO_0003106J18——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101—C90.022———3
Plasma cell neoplasmsD054219——22———3
Chronic hepatitis dD019701———1———1
Hepatitis bD006509———1———1
Hepatitis dD003699EFO_0007304——1———1
HepatitisD006505—K75.9—1———1
Hepatitis aD006506EFO_0007305B15—1———1
Colorectal neoplasmsD015179——11———1
TuberculosisD014376EFO_0000774A15-A19—1———1
Pulmonary tuberculosisD014397EFO_1000049A15—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———6————6
NeoplasmsD009369—C803————3
LeukemiaD007938—C952————2
B-cell chronic lymphocytic leukemiaD015451—C91.12————2
Lymphoid leukemiaD007945—C912————2
LymphomaD008223—C85.92————2
Non-small-cell lung carcinomaD002289——1————1
Renal insufficiencyD051437—N191————1
Prostatic neoplasmsD011471—C611————1
Non-hodgkin lymphomaD008228—C85.91————1
Show 4 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameErythromycin
INNerythromycin
Description
Erythromycin A is an erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively. It is an erythromycin and a cyclic ketone. It is functionally related to an erythronolide A. It is a conjugate base of an erythromycin A(1+).
Classification
Small molecule
Drug classantibiotics (Streptomyces strains)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
Identifiers
PDB—
CAS-ID114-07-8
RxCUI—
ChEMBL IDCHEMBL532
ChEBI ID42355
PubChem CID12560
DrugBankDB00199
UNII ID63937KV33D (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Erythromycin
+
Benzoyl peroxide
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Erythromycin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Erythromycin
+
Sulfisoxazole
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 86,890 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
10,951 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use